Cytokinetics, Incorporated (CYTK) has a consensus analyst rating of Buy, based on 34 analysts covering the stock. Of those, 32 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for CYTK is $92.27, representing a +39.1% upside from the current price of $66.35. Price targets range from a low of $69.00 to a high of $136.00.
